Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

Major U.S. equities indexes were mixed Thursday afternoon as President Donald Trump met with Chinese leader Xi Jinping on trade issues and investors digested several big tech earnings reports.

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.

Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its ...